Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0
|
作者：
Dholaria, Bhagirathbhai R.
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Martin, Thomas G.
Morillo, Daniel
Reece, Donna Ellen
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar J.
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, Marie-Anne Damiette
Wasch, Ralph
van de Donk, Niels W. C. J.
Chari, Ajai
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Univ Hosp Salamanca, Salamanca, Spain
[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA
[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[11] Med Coll Wisconsin, Milwaukee, WI USA
[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[16] Janssen Res & Dev, Spring House, PA USA
[17] Janssen Res & Dev, Antwerp, Belgium
[18] Janssen Biol Europe, Leiden, Netherlands
[19] Freiburg Univ, Med Ctr, Freiburg, Germany
[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[21] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8003
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [41] Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) plus daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
    Siegel, David Samuel DiCapua
    Schiller, Gary J.
    Samaras, Christy Joy
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin W.
    Seet, Christopher
    Talamo, Giampaolo
    Srinivas, Shanthi
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand Marquess
    Fonseca, Gustavo
    Reece, Donna Ellen
    Zafar, Faiza
    Chung, Weiyuan
    Bahlis, Nizar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
    Orlowski, Robert
    Delimpasi, Sosana
    Straub, Jan
    Symeonidis, Argiris
    Pour, Ludek
    Hajek, Roman
    Touzeau, Cyrille
    Bhanderi, Viralkumar
    Pavlicek, Petr
    Robak, Pawel
    Berdeja, Jesus G.
    Matous, Jeffrey V.
    Karlin, Lionel
    Zweegman, Sonja
    Grosicki, Sebastian
    Pluta, Andrzej
    Kambhampati, Suman
    Suryanarayan, Kaveri
    Twumasi-Ankrah, Philip
    Dash, Ajeeta
    Labotka, Richard
    Dimopoulos, Meletios-Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S155
  • [43] EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Quach, Hang
    Dimopoulos, Meletios A.
    Rodriguez-Otero, Paula
    Berdeja, Jesus G.
    Richardson, Paul G.
    Kyada, Margee
    Chu, Shuyu
    Chen, Min
    Abad, Patricia C.
    Morando, Juliane
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [45] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Palumbo, Antonio
    Lisby, Steen
    Basse, Linda
    Wang, Jianping
    Sasser, A. Kate
    Guckert, Mary E.
    Yeh, Howard
    Ahmadi, Tahamtan
    Lokhorst, Henk M.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [46] Treatment Patterns in Patients (pts) with Refractory/Relapsed Multiple Myeloma (RRMM) in Germany between 2016 and 2018
    Merz, Maximilian
    Patel, Vishal
    Kutikova, Lucie
    Lebioda, Andrea
    Schoehl, Martina
    Kellermann, Lenka
    Goldschmidt, Hartmut
    BLOOD, 2019, 134
  • [47] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
    Grosicki, Sebastian
    Mellqvist, Ulf-Henrik
    Pruchniewski, Lukasz
    Crafoord, Jacob
    Trudel, Suzanne
    Min, Chang-Ki
    White, Darrell
    Alegre, Adrian
    Hansson, Markus
    Ikeda, Takashi
    Sunami, Kazutaka
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Koh, Youngil
    BLOOD, 2022, 140 : 4407 - 4408
  • [48] Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
    Spencer, Andrew
    Lentzsch, Suzanne
    Weisel, Katja
    Avet-Loiseau, Herve
    Mark, Tomer M.
    Spicka, Ivan
    Masszi, Tamas
    Lauri, Birgitta
    Levin, Mark-David
    Bosi, Alberto
    Hungria, Vania
    Cavo, Michele
    Lee, Je-Jung
    Nooka, Ajay K.
    Quach, Hang
    Lee, Cindy
    Barreto, Wolney
    Corradini, Paolo
    Min, Chang-Ki
    Scott, Emma C.
    Chanan-Khan, Asher A.
    Horvath, Noemi
    Capra, Marcelo
    Beksac, Meral
    Ovilla, Roberto
    Jo, Jae-Cheol
    Shin, Ho-Jin
    Sonneveld, Pieter
    Soong, David
    Casneuf, Tineke
    Chiu, Christopher
    Amin, Himal
    Qi, Ming
    Thiyagarajah, Piruntha
    Sasser, A. Kate
    Schecter, Jordan M.
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2018, 103 (12) : 2079 - 2087
  • [49] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Belch, Andrew
    White, Darrell
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather J.
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Bahlis, Nizar J.
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Sasser, A. Kate
    Khokhar, Nushmia Z.
    Avet-Loiseau, Herve
    Usmani, Saad Z.
    HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
  • [50] Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
    Avet-Loiseau, Herve
    Casneuf, Tineke
    Chiu, Christopher
    Laubach, Jacob P.
    Lee, Je-Jung
    Moreau, Philippe
    Plesner, Torben
    Nahi, Hareth
    Khokhar, Nushmia Z.
    Qi, Ming
    Schecter, Jordan
    Carlton, Victoria
    Qin, Xiang
    Liu, Kevin
    Wu, Kaida
    Zhuang, Sen H.
    Ahmadi, Tahamtan
    Sasser, A. Kate
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
12345